Portola Pharmaceuticals   Print Page    Close Window

Corporate Profile

Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. Our first commercial product, Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor anticoagulant, is approved in the United States. We are also advancing the clinical development of two ot... Read More

Stock Quote
NASDAQ PTLA (Common Stock)
$34.83 - 1.28
Stock chart for: PTLA.O.  Currently trading at $34.83 with a 52 week high of $67.10 and a 52 week low of $30.10.
03/16/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Upcoming EventsMore >>
Portola Pharmaceuticals, Inc. at the Oppenheimer’s 28th Annual Healthcare Conference
Tuesday, March 20, 2018 10:55 a.m. ET

Archived Events
Portola Pharmaceuticals, Inc. at the Cowen and Company’s 38th Annual Health Care Conference
Tuesday, March 13, 2018 8:40 a.m. ET
DescriptionDue to the severe winter storm conditions in Boston and the impact on travel to and from the area, Portola will not be making its scheduled presentation at the Cowen Healthcare conference.
LocationBoston, MA

Portola Pharmaceuticals Update Call on ANNEXA-4 Study Interim Results
Monday, March 12, 2018 12:30 p.m. ET
Supporting Materials
Download Event Supporting Material Portola ANNEXA-4 Webcast Presentation